Log in

NYSE:TAROTaro Pharmaceutical Industries Stock Price, Forecast & News

$68.20
+0.75 (+1.11 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$67.31
Now: $68.20
$68.55
50-Day Range
$64.21
MA: $67.34
$69.08
52-Week Range
$56.07
Now: $68.20
$99.69
Volume18,100 shs
Average Volume42,964 shs
Market Capitalization$2.61 billion
P/E Ratio10.72
Dividend YieldN/A
Beta0.79
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
Read More
Taro Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone914-345-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$644.77 million
Cash Flow$7.02 per share
Book Value$55.15 per share

Profitability

Net Income$244.24 million

Miscellaneous

Employees1,464
Market Cap$2.61 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

How has Taro Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TARO shares have increased by 5.8% and is now trading at $68.20. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Taro Pharmaceutical Industries.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Taro Pharmaceutical Industries.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings data on Tuesday, May, 19th. The company reported $1.42 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.53 by $0.11. The firm earned $174.94 million during the quarter, compared to the consensus estimate of $168.25 million. Taro Pharmaceutical Industries had a net margin of 37.88% and a return on equity of 11.94%. View Taro Pharmaceutical Industries' earnings history.

What price target have analysts set for TARO?

1 equities research analysts have issued 12 month target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $96.00 to $96.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $96.00 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View analysts' price targets for Taro Pharmaceutical Industries.

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TARO stock have trended negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Taro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a drop in short interest in June. As of June 30th, there was short interest totaling 133,500 shares, a drop of 7.4% from the June 15th total of 144,200 shares. Based on an average daily trading volume, of 35,300 shares, the short-interest ratio is presently 3.8 days. Approximately 1.5% of the company's shares are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ), Mallinckrodt (MNK) and Novo Nordisk A/S (NVO).

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $68.20.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $2.61 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 914-345-9000 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.